Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of classical and non-classical HLA class I antigens in human tumors
Juergen Bukur, Simon Jasinski, Barbara Seliger
Seminars in Cancer Biology (2012) Vol. 22, Iss. 4, pp. 350-358
Closed Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 673
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, et al.
European Journal of Cancer (2017) Vol. 81, pp. 116-129
Closed Access | Times Cited: 506
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai, Junzo Hamanishi, Kaoru Abiko, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 10, pp. 2329-2334
Open Access | Times Cited: 343
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Joana M. Silva, Mafalda Videira, Rogério Gaspar, et al.
Journal of Controlled Release (2013) Vol. 168, Iss. 2, pp. 179-199
Closed Access | Times Cited: 226
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn, Sudha Rao
Molecular Immunology (2017) Vol. 87, pp. 227-239
Open Access | Times Cited: 178
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 138
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Hanchen Xu, Kevin Van der Jeught, Zhuolong Zhou, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 10
Open Access | Times Cited: 121
The theory of tumor ecosystem
Xueman Chen, Erwei Song
Cancer Communications (2022) Vol. 42, Iss. 7, pp. 587-608
Open Access | Times Cited: 78
Clinical Role of Human Leukocyte Antigen in Health and Disease
Youssef M. Mosaad
Scandinavian Journal of Immunology (2015) Vol. 82, Iss. 4, pp. 283-306
Open Access | Times Cited: 174
Antigen processing and immune regulation in the response to tumours
Emma Reeves, Edward James
Immunology (2016) Vol. 150, Iss. 1, pp. 16-24
Open Access | Times Cited: 163
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
Cariad Chester, Katherine Fritsch, Holbrook E. Kohrt
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 162
Multiparametric immune profiling in HPV– oral squamous cell cancer
Zipei Feng, Daniel Bethmann, Matthias Kappler, et al.
JCI Insight (2017) Vol. 2, Iss. 14
Open Access | Times Cited: 162
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
Balázs Győrffy, Giulia Bottai, Thomas Fleischer, et al.
International Journal of Cancer (2015) Vol. 138, Iss. 1, pp. 87-97
Open Access | Times Cited: 149
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Aifen Lin, Wei‐Hua Yan
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 121
The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
Yuxuan Liu, Ahmad Sattarzadeh, Arjan Diepstra, et al.
Seminars in Cancer Biology (2013) Vol. 24, pp. 15-22
Closed Access | Times Cited: 119
Human KIR repertoires: shaped by genetic diversity and evolution
Angela R. Manser, Sandra Weinhold, Markus Uhrberg
Immunological Reviews (2015) Vol. 267, Iss. 1, pp. 178-196
Closed Access | Times Cited: 101
Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response
Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al.
European Urology (2016) Vol. 71, Iss. 5, pp. 776-787
Open Access | Times Cited: 99
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
Michele Maio, Alessia Covre, Elisabetta Fratta, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 18, pp. 4040-4047
Open Access | Times Cited: 96
Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma
Alexander W. Eckert, Claudia Wickenhauser, Paul C. Salins, et al.
Journal of Translational Medicine (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 92
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Yuanzhang Fang, Lifei Wang, Changlin Wan, et al.
Journal of Clinical Investigation (2020) Vol. 131, Iss. 1
Open Access | Times Cited: 88
Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Ya Luo, Jiqiao Yang, Jing Yu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 72
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Solange Peters, Luís Paz-Ares, Roy S. Herbst, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004863-e004863
Open Access | Times Cited: 42
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
Xinan Wang, Giuseppe Lamberti, Alessandro Di Federico, et al.
Annals of Oncology (2024) Vol. 35, Iss. 6, pp. 508-522
Closed Access | Times Cited: 12
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Luca Sigalotti, Elisabetta Fratta, Sandra Coral, et al.
Pharmacology & Therapeutics (2014) Vol. 142, Iss. 3, pp. 339-350
Closed Access | Times Cited: 93
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance
Barbara Seliger, Matthias Kloor, Soldano Ferrone
OncoImmunology (2017) Vol. 6, Iss. 2, pp. e1171447-e1171447
Open Access | Times Cited: 83
Page 1 - Next Page

Scroll to top